RED HOT Contributors


Merck withdraws marketing application for Keytruda in Europe


(Reuters) – Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.

The company’s shares tumbled 8.9 percent to $56.50 in after-hours trading.

Earlier in the day, the U.S. drugmaker said quarterly sales of Keytruda exceeded $1 billion for the first time in the third quarter.

Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.


We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast